Nifedipine interaction with tacrolimus in liver transplant recipients

Annals of Pharmacotherapy

Volumn 31, Issue 5, 1997, Pages 571-575

  Seifeldin, Raafat A ^a   Marcos Alvarez, Amadeo ^b   Gordon, Fredric D ^b   David Lewis, W ^b   Jenkins, Roger L ^b  

^a PFIZER INC   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

drug interactions; nifedipine; tacrolimus; transplantation

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DILTIAZEM; ERYTHROMYCIN; KETOCONAZOLE; NIFEDIPINE; NYSTATIN; PREDNISONE; TACROLIMUS;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; GRAFT REJECTION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER TRANSPLANTATION; METABOLIC INHIBITION; MYCOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0030924777     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100508     Document Type: Article

References (16)

1. Klintmalm GB. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331: 1110-5.
2. Williams R. Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994;334: 423-8.
3. Knight RJ, Kerman RH, Welsh M, Golden D, Schoenberg L, Van Buren CT, et al. Chronic rejection in primary renal allograft recipients under cyclosporine prednisone immunosuppressive therapy. Transplantation 1991;51:355-9.
4. Vincent SH, Karanam BV, Painter SK, Chiu SH. In vitro metabolism of FK506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P-450 3A as the major enzymes responsible for its metabolism. Arch Biochem Biophys 1992;294:454-60.
5. Sattler M, Guengerich FP, Yun CH, Christians U, Swing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-61.
6. Stiff DD, Venkataramanan R, Orasad TNV. Metabolism of FK506 in differentially induced rat liver microsomes. Res Commun Chem Pathol Pharmacol 1992;78:121-4.
7. Christians U, Braun F, Schmidt M, Kosian N, Schiebel HM, Ernst L, et al. Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver graft recipients. Clin Chem 1992;38:2025-32.
8. Miniscalco A, Lundahl J, Regardh CG, Edgar B, Eriksson UG. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Ther 1992;261: 1195-9.
9. Wagner K, Henkel M, Heinemeyer G, Neumayer HH. Interaction of calcium blockers and cyclosporine. Transplant Proc 1988;20(suppl 2):561-8.
10. Henricsson S, Lindholm A. Inhibition of cyclosporine metabolism by other drugs in vitro. Transplant Proc 1988;20:569-71.
11. Kiberd BA. Cyclosporine induced renal dysfunction in human renal allograft recipients. Transplantation 1989; 48:965-9.
12. McNally P, Mistry N, Idle J, Walls J, Feehally J. Calcium channel blockers and cyclosporine metabolism. Transplantation 1989;48:1071.
13. Propper DJ, Whiting PH, Power DA, Edward N, Catto GR. The effect of nifedipine on graft function in renal allograft recipients treated with cyclosporine A. Clin Nephrol 1989;32:62-7.
14. Sketris IS, Methot ME, Nicol D, Belitsky P, Knox MG. Effects of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. Ann Pharmacother 1994;28:1227-31.
15. Iwasaki K, Matsuda H, Nagase K, Shiraga T, Tokuma Y, Uchida K. Effects of twenty three drugs on the metabolism of FK506 by human liver microsomes. Res Commun Chem Pathol Pharmacol 1993;82:209-16.
16. Seifeldin RA, Marcos-Alvarez A, Lewis WD, Gordon FD, Jenkins RL. Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus. Clin Ther 1996;18:491-6.